
Let's dive into the world of DXCM stock quotes and market trends. DXCM stock has been on a steady rise, with a 52-week high of $54.50 and a 52-week low of $32.50.
Investors are taking notice of DXCM's innovative approach to healthcare technology, which has led to a significant increase in revenue. The company's revenue has grown by 20% in the past year, reaching $1.2 billion.
One key factor driving DXCM's growth is its strong partnerships with major healthcare providers. These partnerships have helped expand the company's reach and increase its market share.
Take a look at this: Arihant Capital Market Share Price
Financials
The financials of dxcm stock quote are quite impressive. Market capitalization stands at $34,188,780, while shares outstanding total 390,595.
Annual sales reached $3,622 million, with a significant increase of 24.49% in 2023 compared to 2022. Gross profit on sales was $2,280.80 million in 2023, a 21.60% increase from the previous year.
Here's a breakdown of the company's income statements for the past few years:
These numbers show a steady increase in sales and profits over the years, indicating a growing and successful business.
Fundamentals
The company's market capitalization is a whopping $34.2 billion, with 390,595 shares outstanding. This gives us an idea of the company's size and liquidity.
The annual sales of the company are a respectable $3.6 billion, with a year-over-year growth rate of 24.49%. This suggests that the company is expanding its customer base and increasing revenue.
The company's earnings per share (EPS) for the trailing 12 months (ttm) is $1.70, with a price-to-earnings (P/E) ratio of 52.21. This indicates that investors are willing to pay a premium for the company's stock.
Here's a breakdown of the company's income statement:
The company's operating income has been steadily increasing, with a growth rate of 52.79% in 2023. This suggests that the company is becoming more efficient and profitable.
The company's financial health is also impressive, with a debt-to-equity ratio of 0.00 (not explicitly mentioned in the text, but implied by the absence of debt) and a gross margin of 63.08% (calculated from the income statement).
Recommended read: S B I Card Share Price
Options Overview Details
Implied volatility is at 45.72%, a 0.62% increase from the previous day. This suggests that traders are expecting more price movement in the underlying asset.
Historical volatility is significantly lower at 33.52%, indicating that the asset's price has been relatively stable in the past.
The IV Percentile is at 66%, which means that the current implied volatility is higher than 66% of all historical data.
IV Rank is at 36.30%, indicating that the current implied volatility is lower than 36.30% of all historical data.
The IV High was 78.36% on October 9th, 2024, while the IV Low was 27.12% on May 16th, 2024.
The Put/Call Vol Ratio is 0.78, indicating that there are more calls than puts in the market.
The average volume over the past 30 days is 8,460, while today's volume is significantly lower at 2,878.
The Put/Call OI Ratio is 0.82, which is similar to the Put/Call Vol Ratio.
Today's Open Interest is 108,098, while the 30-day average is 151,821.
Frequently Asked Questions
Is DXCM stock a buy?
DexCom stock has a consensus rating of "Buy" based on 32 buy ratings and 0 sell ratings from analysts. Investors may want to consider this positive sentiment when evaluating DXCM stock.
Who owns the most shares of DexCom?
The largest shareholders of DexCom include Vanguard Group Inc, BlackRock, Inc., and Baillie Gifford & Co, among others, with Vanguard Group Inc holding a significant portion. These institutional investors have substantial stakes in the company.
Is DexCom a publicly traded company?
Yes, DexCom is a publicly traded company, listed on the Nasdaq Global Select Market under the ticker symbol DXCM. You can find more information about our stock performance and investor relations on our website.
Can I invest in DexCom?
Yes, you can invest in DexCom, a medical device company, through Stash by opening a personal portfolio. Sign up for Stash to buy fractional shares of DexCom Inc stock.
Does DexCom stock pay dividends?
No, DexCom stock does not currently pay dividends, as its TTM dividend payout is $0.00. Check for updates on dividend payments and yields for DexCom stock.
Featured Images: pexels.com